To rename polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect and address its endocrine and metabolic features.
Key Findings:
PCOS affects an estimated 170 million women globally and remains underdiagnosed in up to 70% of cases.
The term 'polycystic ovary syndrome' contributed to delayed diagnosis and stigma.
The new name PMOS reflects the disorder's multisystem endocrine and metabolic biology.
Insulin resistance and compensatory hyperinsulinemia were reported in 85% of affected patients, including 75% of lean patients.
Interpretation:
The renaming to PMOS aims to enhance understanding and treatment of the condition by emphasizing its broader implications beyond ovarian dysfunction, including metabolic and cardiovascular health.
Limitations:
Disproportionate representation from higher-income regions may limit the applicability of findings to lower-income areas.
Lower participation from Asia, Africa, and South America raises concerns about the global relevance of the consensus.
Purposive nonprobability sampling may limit generalizability despite broad international engagement.
Conclusion:
The change to PMOS has significant implications for healthcare systems, policy, and research, advancing the understanding and treatment of the condition on a global scale.
